AMN HEALTHCARE SERVICES INC
No SEC Form 4 filings for $AMN in the last 30 days.
See all $AMN insider activity →Bank of America raised its price target for AMN Healthcare Services from $26 to $28. The stock has seen a 5-day change of 34.92 USD, a 1st Jan change of +2.25%, and a 1-year change of +3.53%.
AMN Healthcare (AMN) reported Q2 revenue of $673.2M, up 2% YoY, with net income of $21.2M. Travel nurse and allied staffing revenue grew 10% and 8% YoY, respectively. However, Physician and Leadership Solutions revenue fell 6% and Technology and Workforce Solutions revenue dropped 15% YoY. The company expects these declines to continue in Q3.
BMO Capital maintained an Outperform rating for AMN Healthcare Services (AMN) and raised its price target to $40.00 from $38.00. AMN is currently trading at $33.05, which is 11.2% above its GF Value™ of $29.71, indicating overvaluation. The company has a GF Score™ of 63, reflecting moderate performance, with strengths in profitability and financial strength but weaknesses in growth. Insiders have sold $114,369 worth of shares in the past three months.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning AMN (AMN HEALTHCARE SERVICES INC). Coverage has skewed bullish: 2 bullish, 1 neutral, and 0 bearish.
Recent AMN coverage spans earnings, financial news and sector analysis.
The upward price target suggests potential upside for AMN as analysts see improved valuation.
Earnings beat on profit and travel nurse growth, but mixed segment outlook may cause volatility.
Analyst upgrade may support short‑term upside.
No fresh catalyst; the piece summarizes already‑public performance and outlook.
The earnings beat and raised revenue outlook are the core near-term catalyst, but the article flags ongoing margin risk from wage inflation and pricing pressure.
AlphAI scores every news story that mentions AMN with an AI model for sentiment and relevance, and aggregates insider trades from AMN HEALTHCARE SERVICES INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Bank of America raised its price target for AMN Healthcare Services from $26 to $28. The stock has seen a 5-day change of 34.92 USD, a 1st Jan change of +2.25%, and a 1-year change of +3.53%.
1 min readAMN Healthcare (AMN) reported Q2 revenue of $673.2M, up 2% YoY, with net income of $21.2M. Travel nurse and allied staffing revenue grew 10% and 8% YoY, respectively. However, Physician and Leadership Solutions revenue fell 6% and Technology and Workforce Solutions revenue dropped 15% YoY. The company expects these declines to continue in Q3.
3 min readBMO Capital maintained an Outperform rating for AMN Healthcare Services (AMN) and raised its price target to $40.00 from $38.00. AMN is currently trading at $33.05, which is 11.2% above its GF Value™ of $29.71, indicating overvaluation. The company has a GF Score™ of 63, reflecting moderate performance, with strengths in profitability and financial strength but weaknesses in growth. Insiders have sold $114,369 worth of shares in the past three months.
1 min readAMN Healthcare Services' stock has surged 118.7% year-to-date, outperforming its industry and the S&P 500. Q2 revenues rose 2.3% to $673M, exceeding guidance, with adjusted EPS up 158% YoY. Growth is driven by strong demand in nurse and allied staffing, technology enhancements, and persistent healthcare workforce shortages. The company's 2026 EPS is projected to grow 127.9% to $3.10, with revenues expected to rise 20.9% to $3.30B.
2 min readAMN Healthcare Services reported Q2 2026 sales of $673.24M and returned to profitability. The company also joined the AONL Foundation Corporate Advisory Council. Analysts debate whether earnings momentum and raised guidance will sustain revenue stability amid margin pressures and tighter hospital budgets. AMN projects $2.4B revenue and $2.5M earnings by 2029, but some analysts expect a 9% revenue decline annually.
6 min readAMN Healthcare reported Q2 2026 language services revenue of $69.6m, down 8% YoY due to pricing pressure. Overall revenue rose 2% to $673.2m, with net income at $21.2m. The company acquired Jaide Health for AI interpreting services and expects Q3 revenue of $640m-$655m.
6 min readA Q2 earnings wrap for 39 healthcare providers and services stocks says group revenues beat analysts’ consensus by 1.7% and next-quarter guidance was 1.6% above. It highlights AMN Healthcare Services (AMN) revenue of $673.2M (+2.3% YoY), beating estimates by 7.2%, and stock up 11.7% to $34.41. Other featured names include CVS, AdaptHealth, McKesson, and Encompass Health.
6 min readAMN Healthcare reported Q2 2026 revenue of $673 million, up 2% year over year and 6% above the top end of guidance, with adjusted EPS of $0.77. Adjusted EBITDA was $73 million (10.9% margin) after $27 million in nonrecurring billing true-ups. Q3 revenue guidance is $640 million to $655 million. AMN also authorized share repurchases and acquired Jaide Health and ESSENTIAL.
6 min readAMN Healthcare Services reported Q2 revenue of $673.2 million, above analysts’ $628.2 million estimate, and adjusted EPS of $0.77 versus $0.19. Management attributed results to strong Nurse and Allied Solutions demand, including travel nurse and allied volumes, plus higher labor disruption revenue and improved search and international execution. Q3 revenue guidance midpoint was $647.5 million.
6 min readThe article highlights three publicly traded stocks that, according to analyst expectations and reported results, beat or met second-quarter earnings. Allegiant Travel (ALGT) reportedly earned 15 cents vs a 3-cent estimate. IMAX (IMAX) reported 43 cents vs 30 cents. AMN Healthcare (AMN) met estimates at 44 cents per share.
3 min read
